News

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

According to the company, the priority review voucher would be issued upon approval of ATSN-201, a gene therapy product candidate.

The LIGHTHOUSE study a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial is currently investigating the safety and tolerability of ASTN-201 for XLRS.

US District Court Judge Anne Nardacci, presiding in the Northern District of New York, ruled David Kwiat, MD, and Kwiat Eye and Laser Surgery PLLC illegally retaliated against the employee based on protected activity.

Physicians share comprehensive approaches during roundtable discussion.

Smaller surgeries, in greater numbers, await new glaucoma specialists

The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.

A team of researchers from Portugal and Belgium presented a paper highlighting the case of a patient with conjunctival CAM and offered an overview of the differential diagnosis and management of pigmented lesions of the conjunctiva.

Tim Cherry, PhD, and Debarshi Mustafi, MD, PhD, have been awarded a $150,000 Clinical & Research Synergy Pilot Award from Seattle Children’s Research Institute to determine the genetic causes of unsolved inherited retinal diseases.

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

Determining the medication’s safety and efficacy for paediatric patients

The authors explained that estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes.

Lupin has successfully completed a clinical study of LUBT010, a ranibizumab biosimilar to Lucentis

The FDA has a 60-day filing review period to determine whether the NDA submission is complete and acceptable for review.

The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration

According to the company, the FDA approval strengthens its biosimilar position in the US market.

Diabetic Retinopathy ranked as the fifth most common cause of blindness among adults aged 50 and older in 2020 according to data from the Global Burden of Disease study. Aude Couturier, MD shares her experience of using advanced imaging technologies to optimize diagnosis and surgical management of her DR patients in our latest Case of the Month.

Stabilising keratoconus and improving vision using ELZA-PACE customised CXL

Researchers conducted a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated rhegmatogenous retinal detachment at the Wilmer Eye Institute from January 2008 to December 2018.

Researchers conducted a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated rhegmatogenous retinal detachment at the Wilmer Eye Institute from January 2008 to December 2018.

The CPT code is the first to report photobiomodulation therapy in retinal disease.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.

The device features real-time feedback and other features, allowing residents to hone their skills and expand options for practicing one of the most needed procedures in the country.

The SOL-R clinical trial of is deemed appropriate for use as Ocular Therapeutix’s second adequate and well controlled study of axitinib intravitreal implant.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

A postcard from the American Society of Retina Specialists meeting in Stockholm

The ALLY Adaptive Cataract Treatment System will be the first EU ALLY commercial installation